ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and steroids"

  • Abstract Number: 496 • 2018 ACR/ARHP Annual Meeting

    Heart Failure Risk Among Patients with Rheumatoid Arthritis: Association with Anti-Rheumatic Drugs

    Michael Ahlers1, C. Michael Stein2, Cecilia P. Chung2, Michelle J. Ormseth3, Eric Farber-Eger3 and Deepak Gupta4, 14906 illinois avenue, Vanderbilt University School of Medicine, Nashville, TN, 2Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 3Vanderbilt University Medical Center, Nashville, TN, 4Internal Medicine - Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of coronary artery disease (CAD), but the association with heart failure (HF) is less characterized.  We…
  • Abstract Number: 611 • 2018 ACR/ARHP Annual Meeting

    Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort

    Yoko Shimizu1, Eiichi Tanaka1, Eisuke Inoue1,2, Kumiko Saka1, Eri Sugano1, Naohiro Sugitani1,3, Moeko Ochiai1, Rei Yamaguchi1, Naoki Sugimoto1, Ayako Nakajima1,3, Katsunori Ikari1, Atsuo Taniguchi1 and Hisashi Yamanaka4, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, 3Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, 4Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: After the introduction of Biological Disease-Modifying Anti-Rheumatic-Drugs (bDMARDs) for the treatment of patients with active rheumatoid arthritis (RA), clinical remission has become an achievable…
  • Abstract Number: 627 • 2018 ACR/ARHP Annual Meeting

    Corticosteroid Utilization before and after Initiation of Biologic Dmards between Patients with Rheumatoid Arthritis

    Burcu Yagız1, Belkıs Nihan Coşkun2, Sedat Kiraz3, Ihsan Ertenli4, Orhan Kucuksahin5, Ediz Dalkiliç6, Cemal Bes7, Nilufer Alpay Kanitez8, Timucin Kasifoglu9, Hakan Emmungil10, Pamir Atagunduz11, Suleyman Serdar Koca12, Muhammet Cinar13, Aşkın Ateş14, Servet Akar15, Onay Gercik16, Duygu Ersozlu Bakirli17, Veli Yazisiz18, Gezmis Kimyon19, Nazife Sule Yasar Bilge20, Muge Aydin Tufan21, Ridvan Mercan22, Burak Oz12, Zeynel Abidin Akar12, Omer Karadag23, Bahar Kelesoglu24, Sedat Yılmaz25, Sezin Turan26, Yavuz Pehlivan2, Ender Terzioglu27, Levent Kilic23, Sukran Erten28, Koray Tascilar29 and Umut Kalyoncu30, 1Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, 2Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, 3Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, 4Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, 5Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, 6Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, 7Department of Rheumatology, Health Sciences University Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, 8Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey, 9Department of Internal Medicine, Division of Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, 10Department of Internal Medicine, Division of Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, 11Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 12Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, 13Division of Rheumatology, Gülhane Military Medical Academy, School of Medicine, Ankara, Turkey, 14Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, 15Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, 16Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, 17PsART study group, Adana, Turkey, 18Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, 19Rheumatology, Hatay Mustafa Kemal University Faculty of Medicine, Hatay, Turkey, 20Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, 21Rheumatology, Cukurova University School of Medicine, Adana, Turkey, 22Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, 23Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 24Rheumatology, Ankara University, Ankara, Turkey, 25Division of Rheumatology, Gülhane Military Medical Academy, Faculty of Medicine, Ankara, Turkey, 26Trakya University Medical Faculty, Edirne, Turkey, 27Division of Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, 28PsART study group, Ankara, Turkey, 29Rheumatology, Okmeydani Research and Training Hospital, Istanbul, Turkey, 30Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory, systemic autoimmune disease that causes several health problems, such as pain, joint destruction and loss of function.…
  • Abstract Number: 2340 • 2018 ACR/ARHP Annual Meeting

    The Impact of Chronic Glucocorticoid Use Amongst Patients with Rheumatoid Arthritis: A Qualitative Study

    Jonathan Cheah1,2, Sarah Young3, Susan M. Goodman4,5, Catherine Hill6,7, Susan Beard8, Pamela Richards9, Sarah Mackie10, Joanna Robson11,12 and Iris Navarro-Millán5,13, 1Medicine, Hospital for Special Surgery, New York, NY, 2Medicine, Weill Cornell Medicine, New York, NY, 3Binghamton University, Binghamton, NY, 4Rheumatology, Weill Cornell Medicine, New York, NY, 5Hospital for Special Surgery, New York, NY, 6The Queen Elizabeth Hospital, Adelaide, Australia, 7Medicine, The University of Adelaide, Adelaide, Australia, 8Patient Research Partner, Adelaide, Australia, 9Patient Research Partner, Bristol, United Kingdom, 10NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, 11Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, 12School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, 13Weill Cornell Medicine, New York, NY

    Background/Purpose: Glucocorticoids (GCs) have well documented adverse effects. However, the absolute risk and importance of these effects have not been well documented from the perspective…
  • Abstract Number: 435 • 2017 ACR/ARHP Annual Meeting

    Characteristics of Rheumatoid Arthritis Patients Who Have a DMARD Interruption and the Impact of Using a Bridging Medication on Clinical and Patient Reported Outcomes

    Christine Iannaccone1, Michelle Frits2, Taysir G. Mahmoud3, Gabriela Maica4, Jonathan Coblyn5, Michael Weinblatt2 and Nancy A. Shadick6, 1Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, 5Department of Rheumatology, Brigham & Womens Hospital, Boston, MA, 6Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: It is common for RA patients to interrupt their DMARD use due to events like infection, surgery, or pregnancy. Many RA patients may need…
  • Abstract Number: 1801 • 2017 ACR/ARHP Annual Meeting

    Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population

    J. Bradford Rice1, Alan White1, Andrea Lopez1, Aneesha Wagh1, Yimin Qin2, Ghaith Mitri2, Laura Bartels-Peculis2, Gosia Ciepielewska2 and Winnie Nelson3, 1Analysis Group, Inc., Boston, MA, 2Mallinckrodt Pharmaceuticals, Hampton, NJ, 3Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ

    Background/Purpose:  Corticosteroids (CS) are commonly used for rheumatologic conditions, and known to cause systemic adverse events (AEs), particularly when used at high doses for prolonged…
  • Abstract Number: 334 • 2016 ACR/ARHP Annual Meeting

    Predictors of Fragility Fractures in Patients with Rheumatoid Arthritis Not on Steroids: An Observational Study

    Sarah Dyball1 and Marwan Bukhari2, 1University Hospital South Manchester, Manchester, United Kingdom, 2Royal Lancaster Infirmary, Lancaster, United Kingdom

    Background/Purpose:   Patients with rheumatoid arthritis (RA) have an increased fracture risk, however, this is confounded by a coexisting use of steroids. This study aims…
  • Abstract Number: 438 • 2016 ACR/ARHP Annual Meeting

    Glucocorticoid Adverse Effects – the Patient Perspective

    Rachel Black1, Susan M. Goodman2, Carlee Ruediger3, Susan Lester4, Sarah Mackie5 and Catherine Hill3, 1Department of Medicine, The University of Adelaide, Adelaide, Australia, 2Medicine, Hospital for Special Surgery, New York, NY, 3Medicine, The University of Adelaide, Adelaide, Australia, 4Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, 5NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Glucocorticoid (GC) use and adverse effects (AEs) are prevalent in rheumatic diseases, yet there is no standardized patient-reported outcome measure to assess benefit and…
  • Abstract Number: 2039 • 2014 ACR/ARHP Annual Meeting

    Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi-Years before Clinical Onset (Pre-RA) Than in Non-RA Matched Control (CN) Subjects

    Alfonse T. Masi, Azeem A. Rehman and Jean C. Aldag, Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL

    Background/Purpose: Dysregulations in androgenic-anabolic (A-A) steroids and cytokines are recognized in RA and pre-RA subjects (Rheum Dis Clin N Am 2005; 31: 131-60). However, deviations…
  • Abstract Number: 2357 • 2013 ACR/ARHP Annual Meeting

    Confounding By Indication Distorts The Relationship Between Steroid Use and Cardiovascular Disease In Rheumatoid Arthritis

    Alper M. van Sijl1, Maarten Boers2, Alexandre E. Voskuyl1 and Mike T. Nurmohamed1, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Glucocorticoids (GC) are among the most effective drugs in rheumatoid arthritis (RA), but concerns over long-term side effects have not been resolved. Recent studies…
  • Abstract Number: 1461 • 2013 ACR/ARHP Annual Meeting

    Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population

    Boulos Haraoui1, Algis V Jovaisas2, William G. Bensen3, Rafat Y. Faraawi4, John T. Kelsall5, Sanjay Dixit6, Emmanouil Rampakakis7, John S. Sampalis7, Francois Nantel8, Susan M. Otawa9, Allen J. Lehman9 and May Shawi10, 1Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, 2Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 3Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 4Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, 5Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 6McMaster University, Hamilton, ON, Canada, 7JSS Medical Research, Montreal, QC, Canada, 8Janssen Inc., Toronto, ON, Canada, 9Medical Affairs, Janssen Inc., Toronto, ON, Canada, 10Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

    Background/Purpose: The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
  • Abstract Number: 1053 • 2013 ACR/ARHP Annual Meeting

    Physician Proclivity To Use Oral Glucocorticoids Among Rheumatoid Arthritis Patients

    Huifeng Yun1, Fenglong Xie2, Elizabeth S. Delzell1, Lang Chen3, Emily Levitan1, James Lewis4, Kenneth G. Saag5, Timothy Beukelman6, Kevin L. Winthrop7, John Baddley8 and Jeffrey R. Curtis9, 1Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Medicine, University of Pennsylvania, Philadelphia, PA, 5Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 6Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 8Medicine, University of Alabama at Birmingham, Birmingham, AL, 9University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL

    Background/Purpose: It is unclear if the elevated risks of adverse events in rheumatoid arthritis (RA) patients are due to use of biologics or DMARDs, glucocorticoids…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology